Vascular Graft Market

Market Overview The global vascular graft market is projected to expand significantly, from USD 1.41 billion in 2025 to USD 2.21 billion by 2031, with a 7.78% CAGR. These specialized medical devices, crafted from synthetic or biological materials, are essential for restoring blood flow in diseased or damaged vessels. This growth is primarily fueled by the escalating prevalence of cardiovascular diseases and diabetes, which necessitate critical surgical interventions such as bypass procedures and hemodialysis access. An aging global population, increasingly susceptible to arterial obstructions, further amplifies this demand, with approximately 589 million adults living with diabetes globally in 2025, underscoring the immense need for vascular reconstruction. This need is further evidenced by 19.41 million global deaths from cardiovascular disease in 2021 and 131,564 people starting ESRD treatment in the US in 2023, driving strong market activity as reflected by Terumo Corporation's 12.4% year-on-year revenue increase in its Cardiac and Vascular Company segment in 2025. However, a major impediment to market expansion is the persistent challenge regarding the long-term biocompatibility and patency of these devices, especially synthetic grafts. Post-operative complications like thrombosis, infection, and intimal hyperplasia frequently lead to graft failure and costly re-interventions. These adverse biological responses deter surgeons, particularly for small-diameter vessels where synthetic grafts historically show higher failure rates compared to autologous options, limiting widespread adoption and hindering market capitalization on the more than 200 million people globally affected by peripheral artery disease in 2025. Market Driver The escalating global prevalence of cardiovascular and peripheral vascular diseases is the foremost determinant propelling the demand for vascular grafts. As atherosclerosis and arterial obstructions become more widespread, the necessity for surgical bypass procedures to restore blood flow significantly increases, directly boosting the utility of synthetic and biological grafts. This trend is particularly acute in regions dealing with aging populations and lifestyle-associated risk factors, where vascular reconstruction is often the only viable option to prevent amputation or mortality. According to the American Heart Association, in the '2025 Heart Disease and Stroke Statistics Update', cardiovascular disease accounted for approximately 19.41 million global deaths in 2021, a figure that highlights the critical scale of the patient population requiring potential vascular interventions. Simultaneously, the increasing incidence of End-Stage Renal Disease (ESRD) requiring hemodialysis access acts as a parallel growth catalyst. Vascular grafts, particularly arteriovenous (AV) grafts, are essential for patients who are unsuitable for native fistulas, serving as a vital lifeline for long-term dialysis therapy. This segment is witnessing sustained volume growth as kidney failure rates rise due to comorbidities like diabetes and hypertension. According to the United States Renal Data System, in the '2025 Annual Data Report', approximately 131,564 people started treatment for ESRD in the United States in 2023 alone. Reflecting the broader commercial impact of these high-demand clinical areas, according to Terumo Corporation, in 2025, revenue in its Cardiac and Vascular Company segment increased by 12.4% year-on-year, signaling robust market activity driven by these therapeutic needs. Market Challenge The major impediment restricting the expansion of the Global Vascular Graft Market is the persistent issue regarding the long-term biocompatibility and patency of synthetic devices. Adverse biological responses, specifically thrombosis, infection, and intimal hyperplasia, frequently result in graft occlusion, necessitating complex and expensive re-interventions. These complications create a substantial economic and clinical burden on healthcare systems, causing surgeons to remain hesitant about adopting synthetic grafts for small-diameter vessels where failure rates are historically elevated. This lack of clinical confidence limits the widespread utilization of off-the-shelf commercial products, thereby reducing the total addressable market for manufacturers. The impact of this limitation is magnified by the sheer volume of patients requiring durable revascularization who are currently underserved by existing technology. According to the American Heart Association, in 2025, peripheral artery disease affected more than 200 million people globally, representing a vast demographic critically dependent on successful surgical outcomes. However, the high probability of post-operative failure in synthetic options undermines their viability as a standard of care. Consequently, the market struggles to capitalize on this growing patient base, as the risks associated with graft rejection and mechanical failure directly dampen revenue growth and slow the rate of product penetration. Market Trends The market is undergoing significant transformation driven by key trends. The adoption of minimally invasive Endovascular Aneurysm Repair (EVAR) techniques is shifting the competitive landscape from open surgical procedures to catheter-based interventions. This trend, aimed at minimizing operative trauma and reducing recovery times for patients with aortic aneurysms, compels manufacturers to develop lower-profile and more flexible stent-graft systems to accommodate complex anatomies, as demonstrated by Medtronic plc's 6% year-over-year net sales increase in its Structural Heart & Aortic division in fiscal year 2025. Concurrently, the development of off-the-shelf Tissue-Engineered Vascular Grafts (TEVGs) offers a promising solution to the biocompatibility issues associated with synthetic alternatives. These bioengineered constructs are designed for universal implantation, eliminating the need for autologous vein harvesting and reducing risks of infection and rejection. The commercial progression of this technology, providing immediate biological conduits for trauma and vascular repair, is highlighted by Humacyte, Inc.'s reported sales of $703,000 for its acellular tissue-engineered vessel, Symvess, in the third quarter of 2025, signaling its initial market penetration. Key Market Players * Abbott Laboratories * Braun Melsungen AG * Bard Peripheral Vascular Inc. * Cordis Corporation * Cook Medical LLC * Endologix Inc. * Getinge Group * LeMaitre Vascular Inc. * Medtronic PLC * Terumo Medical Corporation. Report Scope In this report, the Global Vascular Graft Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Vascular Graft Market, By Product * Hemodialysis Access Graft * Endovascular Stent Graft * Peripheral Vascular Graft * Coronary Artery By-pass Graft # Vascular Graft Market, By Application * Aneurysms * Kidney Failure * Vascular Occlusion * Coronary Artery Diseases * Other Applications # Vascular Graft Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Vascular Graft Market. Available Customizations: Global Vascular Graft Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).